Stock PHAT PHATHOM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
11.35 USD +3.65% Intraday chart for Phathom Pharmaceuticals, Inc. +7.08% +24.32%
Jun. 11 Transcript : Phathom Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:40 PM
May. 09 Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024

Evolution of the average Target Price on Phathom Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

44ff31bb803ef7fd7b10a416f7.WVBYhe4qUsjaAkNwdl_6W_0sX1sQojG4p2C-4ty4D9I.FhM2wq8fF6uJewsGPRWpNbUfMDFE1HmI9Bfrk5GJfv81aR3Hg3I1qpNycw~68bc257babcd36d6c19c8aa0c6f6d1ee

Analyst Recommendations on Phathom Pharmaceuticals, Inc.

Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target MT
Needham Raises Price Target on Phathom Pharmaceuticals to $26 From $23, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on Phathom Pharmaceuticals to $10 From $9, Maintains Neutral Rating MT
HC Wainwright Initiates Coverage on Phathom Pharmaceuticals with Buy Rating, $28 Price Target MT
Craig-Hallum Starts Phathom Pharmaceuticals at Buy With $21 Price Target MT
BMO Capital Adjusts Price Target on Phathom Pharmaceuticals to $30 From $35, Maintains Outperform Rating MT
Needham Adjusts Price Target on Phathom Pharmaceuticals to $23 From $25, Maintains Buy Rating MT
BMO Capital Trims Price Target on Phathom Pharmaceuticals to $35 From $38, Affirms Outperform Rating MT
Needham Adjusts Phathom Pharmaceuticals Price Target to $25 From $38, Maintains Buy Rating MT
BMO Capital Cuts Price Target on Phathom Pharmaceuticals to $38 From $45, Maintains Outperform Rating MT
Guggenheim Adjusts Price Target on Phathom Pharmaceuticals to $30 From $42, Maintains Buy Rating MT
Jefferies Starts Phathom Pharmaceuticals at Buy With $16 Price Target MT
Needham Adjusts Phathom Pharmaceuticals' Price Target to $38 from $44, Keeps Buy Rating MT
Goldman Sachs Adjusts Price Target for Phathom Pharmaceuticals to $15 From $32, Retains Neutral Rating MT
PHATHOM PHARMACEUTICALS : Guggenheim Adjusts Phathom Pharmaceuticals PT to $75 From $66, Maintains Buy Rating MT
PHATHOM PHARMACEUTICALS : Goldman Sachs Upgrades Phathom Pharmaceuticals to Neutral From Sell, Adjusts Price Target to $48 From $40 MT
PHATHOM PHARMACEUTICALS : BMO Capital Starts Phathom Pharmaceuticals at Outperform With $63 Price Target MT
PHATHOM PHARMACEUTICALS : Guggenheim Starts Phathom Pharmaceuticals at Buy With $60 Price Target MT
PHATHOM PHARMACEUTICALS : Needham Adjusts Phathom Pharmaceuticals' Price Target to $55 from $45, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.35 USD
Average target price
22.29 USD
Spread / Average Target
+96.35%
High Price Target
28 USD
Spread / Highest target
+146.70%
Low Price Target
10 USD
Spread / Lowest Target
-11.89%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Phathom Pharmaceuticals, Inc.

Stifel Nicolaus
Needham & Co.
Goldman Sachs
HC Wainwright
Craig-Hallum
BMO Capital
Guggenheim
Jefferies & Co.

Ratings for Phathom Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PHAT Stock
  4. Consensus Phathom Pharmaceuticals, Inc.